<DOC>
	<DOCNO>NCT00879112</DOCNO>
	<brief_summary>A Phase 2 randomize , placebo control study assess efficacy , safety , tolerability MB07811 give orally subject primary hypercholesterolemia 12 week follow 6-week drug phase .</brief_summary>
	<brief_title>Study MB07811 Subjects With Hypercholesterolemia</brief_title>
	<detailed_description>This outpatient , Phase 2 , multicenter , double-blind , placebo-controlled , randomize , parallel-group study assess efficacy , safety , tolerability MB07811 give orally subject primary hypercholesterolemia 12 week . There 3- 6-week screening/run-in period , include washout lipid-modifying therapy ( need ) prior randomization . Eligible subject randomize ( 1:1:1:1 ) placebo , 3 different dos MB07811 12 week . After double-blind treatment phase , randomize subject proceed 6-week off-drug phase . Assessments include : laboratory test , adverse event ( AEs ) , electrocardiogram ( ECGs ) , vitals , PK sample .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Body mass index ( BMI ) 18.50 40 kg/m2 inclusive screening ; Fasting serum LDLC â‰¥145 mg/dL Q2 Q3 visit ; Fasting mean serum LDLC &lt; 220 mg/dL Q2 Q3 ; History clinically significant cardiovascular disease Uncontrolled hypertension Significant sinus bradycardia define &lt; 40 beat per minute ( bpm ) ; Personal family history clinically significant unexplained syncope , nearsyncope unexplained sudden death QT syndrome ; Holter monitor report demonstrate abnormality clinically significant , include limited PVC frequency &gt; 1 per minute , alert criterion condition require evaluation ; History clinical significant arrhythmia ; Resting 12lead ECG show QTc &gt; 450 msec &lt; 360 msec ( male female ) , tachyarrhythmia morphology change , clinically significant abnormality ; Any cardiovascular event require hospitalization ; History presence thyroid disorder metabolic/endocrine disorder affect lipid glucose ; Exceptions : polycystic ovarian syndrome ( PCOS ) impair glucose tolerance ( IGT ) allow . Liver disease , gallbladder disease , Gilbert 's syndrome , biopsyproven nonalcoholic steatohepatitis ( NASH ) , positive serology hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ; Exceptions : gallbladder disease treat cholecystectomy History human immunodeficiency virus ( HIV ) ; Subjects prior history malignancy past 5 year ; Exceptions : Subjects previous history basal squamous cell carcinoma skin , cervical cancer situ allow successfully treat ; History myopathy , include history statininduced myopathy ; History intolerance statin ( e.g. , myalgia , elevate liver test ) ; History clinically significant psychiatric disorder , include limited bipolar disorder , major depressive disorder , psychosis ; Renal dysfunction ; Alcohol and/or drug abuse within 12 month prior screen ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Hyperlipidemia</keyword>
</DOC>